Abbott Laboratories is a diversified healthcare supplier with a focus on medical devices, nutrition, diagnostics, and pharmaceuticals. The company experienced a surge in share price due to COVID-19 ...

Abbott posted strong organic growth of 11% in Q4 when excluding Covid testing sales. This year the stock will hit a milestone: 400 consecutive quarterly dividend payments. But consistency doesn't come ...

A new automation system from Abbott, designed to improve workflows in clinical lab settings, has been granted FDA approval. The system, GLP systems Track, uses a self-propelled carrier system that ...

Abbott Laboratories reported strong Q4 2023 earnings, with year-over-year growth in EPS and revenue. The company's 2024 guidance projects further growth and improved ...

A concussion test that Abbott Labs hopes someday could be used by sports team trainers and at urgent care clinics is now available for rapid use at the bedside, without having to send a sample to a ...

Abbott is the name behind many well-known products.

Sales at Abbott Laboratories' diagnostics unit dropped in the second quarter as demand for COVID-19 tests slumped. The company beat profit and sales estimates on strong sales of its medical devices.

Abbott Laboratories (NYSE:ABT) will release its quarterly earnings report on Wednesday, 2024-10-16. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Abbott ...